-
公开(公告)号:US20170166578A1
公开(公告)日:2017-06-15
申请号:US15039607
申请日:2014-12-17
Applicant: Merck Sharp & Dohme Corp.
Inventor: William K. Hagmann , Bing Li , Jason W. Szewczyk , Bowei Wang , Dann Parker , Timothy Blizzard , Hubert Josien , Purakkattle Biju , Harry Chobanian , Candido Gude , Ravi P. Nargund , Barbara Pio , Qun Dang , Linus S. Lin , Bin Hu , Mingxiang Cui , Zhengxia Chen , Meibi Dai , Zaihong Zhang , Ying Lv , Lili Tian
IPC: C07D493/04 , C07D213/64 , A61K31/44 , C07D409/12 , A61K31/4436 , C07D401/04 , A61K31/4545 , C07D471/04 , A61K31/437 , C07D405/12 , A61K31/4433 , C07D401/12 , A61K31/4439 , A61K31/443 , C07D239/34 , A61K31/505 , C07D451/06 , A61K31/46 , C07D221/20 , A61K31/438 , A61K31/506 , C07D213/74 , C07D417/04 , A61K45/06
CPC classification number: C07D493/04 , A61K31/437 , A61K31/438 , A61K31/44 , A61K31/443 , A61K31/4433 , A61K31/4436 , A61K31/4439 , A61K31/4545 , A61K31/46 , A61K31/505 , A61K31/506 , A61K45/06 , C07D213/64 , C07D213/74 , C07D221/20 , C07D239/34 , C07D401/04 , C07D401/12 , C07D405/12 , C07D409/12 , C07D417/04 , C07D451/06 , C07D471/04
Abstract: The present invention relates to a compound represented by formula (I): and pharmaceutically acceptable salts thereof. The compounds of formula I are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号:US09604998B2
公开(公告)日:2017-03-28
申请号:US14768245
申请日:2014-02-12
Applicant: MERCK SHARP & DOHME CORP.
Inventor: Alexander Pasternak , Reynalda Keh DeJesus , Fa-Xiang Ding , Shuzhi Dong , Jessica L. Frie , Xin Gu , Jinlong Jiang , Aurash Shahripour , Barbara Pio , Haifeng Tang , Shawn Walsh
IPC: A61K31/401 , C07D498/04 , A61K31/5383 , C07D487/04 , C07D519/00 , A61K31/403 , A61K31/41 , A61K31/4178 , A61K31/4184 , A61K31/4422 , A61K31/4985 , A61K31/55 , A61K31/675 , A61K45/06
CPC classification number: C07D498/04 , A61K31/401 , A61K31/403 , A61K31/41 , A61K31/4178 , A61K31/4184 , A61K31/4422 , A61K31/4985 , A61K31/5383 , A61K31/55 , A61K31/675 , A61K45/06 , C07D487/04 , C07D519/00 , A61K2300/00
Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure, kidney disease, edema, and conditions associated with excessive salt and water retention.
-
公开(公告)号:US09469608B2
公开(公告)日:2016-10-18
申请号:US14443470
申请日:2013-11-15
Applicant: Merck Sharp & Dohme Corp.
Inventor: Harry Chobanian , Tesfaye Biftu , Barbara Pio , Zhicai Wu
IPC: C07D207/16 , C07D207/34 , C07D401/14 , C07D401/06 , C07D405/06 , C07D409/06 , C07D403/06 , C07D417/06
CPC classification number: C07D207/16 , C07D207/34 , C07D401/06 , C07D401/14 , C07D403/06 , C07D405/06 , C07D409/06 , C07D417/06
Abstract: Compounds of the invention, which may be useful in inhibiting thrombin and associated thrombotic occlusions, have the following structure: or a pharmaceutically acceptable salt thereof, wherein m is 0 or 1; R is a heterocycle, —(CR8R9)1-2NH2, or —(CR8R9)1-2OH, wherein R8and R9, each time in which they occur, are independently H, C1-6alkyl, —CH2F, —CHF2, CF3or —CH2OH; W is a) —CHR1R2, where R1is —C(CH3)3, and R2is —(CH2)1-2OH, b) a 5- or 6-membered unsubstituted or substituted heterocycle having 1 or 2 heteroatoms selected from N and O, wherein substituted heterocycle is substituted with R3, c) a 9- or 10-membered unsubstituted or substituted heterocycle having 1 or 2 heteroatoms selected from N, O and S, wherein substituted heterocycle is mono-substituted with R3, or disubstituted with R3and R4, or d) a 3-, 4-, or 5-membered carbocyclic ring which is unsubstituted, mono-substituted with R3, di-substituted with R3and R4, or tri-substituted with R3, R4and R5; R3is —CF3, —COOH, —COOR7, —C(O)R6, —CH(OH)R6, —CH2R6, R6, ═O, halogen, R7, —OH, —NH2, or —NHSO2R7; and R10is H or C1-6alkyl.
-
公开(公告)号:US20160280626A1
公开(公告)日:2016-09-29
申请号:US15034189
申请日:2014-12-01
Applicant: Merck Sharp & Dohme Corp.
Inventor: Thomas Bara , Harry R. Chobanian , Yan Guo , Hubert Josien , Michael Miller , Barbara Pio , Christopher W. Plummer , Cangming Yang , Dong Xiao
IPC: C07C59/72 , C07D213/64 , A61K31/44 , C07D209/08 , A61K31/404 , C07D231/12 , A61K31/415 , C07D417/04 , A61K31/427 , C07D471/04 , A61K31/437 , C07D249/04 , A61K31/4192 , C07D333/24 , A61K31/381 , C07C255/59 , A61K31/277 , C07D221/04 , A61K31/435 , A61K45/06 , A61K31/192
CPC classification number: C07C59/72 , A61K31/192 , A61K31/277 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/4192 , A61K31/427 , A61K31/435 , A61K31/437 , A61K31/44 , A61K45/06 , C07C255/59 , C07C2601/02 , C07C2601/14 , C07C2602/06 , C07C2602/08 , C07D207/333 , C07D209/08 , C07D209/12 , C07D213/64 , C07D221/04 , C07D231/12 , C07D249/04 , C07D277/42 , C07D333/24 , C07D417/04 , C07D471/04 , A61K2300/00
Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
15.
公开(公告)号:US20160002259A1
公开(公告)日:2016-01-07
申请号:US14768245
申请日:2014-02-12
Applicant: Alexander PASTERNAK , Reynalda Keh DE JESUS , Fa-xiang DING , Shuzhi DONG , Jessica FRIE , Xin GU , Jinlong JIANG , Aurash SHAHRIPOUR , Barbara PIO , Haifeng TANG , Shawn WALSH , MERCK SHARP & DOHME CORP.
Inventor: Alexander Pasternak , Reynalda Keh DeJesus , Fa-Xiang Ding , Shuzhi Dong , Jessica L. Frie , Xin Gu , Jinlong Jiang , Aurash Shahripour , Barbara Pio , Haifeng Tang , Shawn Walsh
IPC: C07D498/04 , A61K45/06 , A61K31/4985 , A61K31/5383 , C07D487/04
CPC classification number: C07D498/04 , A61K31/401 , A61K31/403 , A61K31/41 , A61K31/4178 , A61K31/4184 , A61K31/4422 , A61K31/4985 , A61K31/5383 , A61K31/55 , A61K31/675 , A61K45/06 , C07D487/04 , C07D519/00 , A61K2300/00
Abstract: The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure, kidney disease, edema, and conditions associated with excessive salt and water retention.
Abstract translation: 本发明提供式I化合物及其药学上可接受的盐,它们是ROMK(Kir1.1)通道的抑制剂。 该化合物可以用作利尿剂和/或利尿钠剂,并用于治疗和预防包括心血管疾病如高血压,心力衰竭,肾脏疾病,水肿以及与过量的盐和水保留有关的病症的医学病症。
-
16.
公开(公告)号:US20140309213A1
公开(公告)日:2014-10-16
申请号:US14353804
申请日:2012-10-25
Applicant: Merck Sharp & Dohme Corp.
Inventor: Shawn P. Walsh , Alexander Pasternak , Reynalda K. DeJesus , Haifeng Tang , Barbara Pio , Aurash Shahripour , Kevin M. Belyk , Harry R. Chobanian , Yan Guo , Jessica L. Frie , Zhi-Cai Shi , Helen Chen , Timothy A. Blizzard , Brian Cato
IPC: C07D471/08 , C07D498/08 , C07D487/18 , C07D405/12 , C07D405/14 , C07D487/08
CPC classification number: C07D471/08 , C07D405/12 , C07D405/14 , C07D407/12 , C07D409/12 , C07D409/14 , C07D487/08 , C07D487/18 , C07D491/08 , C07D498/08
Abstract: This invention relates to compounds of Formula I-VI having the following general structure: Z1—Y1—(CH2)n1—R—(CH2)n2—Y2—Z2 wherein R is a 6-8 membered saturated heterocyclic ring having 2 Nitrogen atoms connected with —(CH2)n1— and —(CH2)n2—, respectively, and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.
Abstract translation: 本发明涉及具有以下一般结构的式I-VI化合物:Z1-Y1-(CH2)n1-R-(CH2)n2-Y2-Z2其中R是具有2个氮原子的6-8元饱和杂环 分别与 - (CH2)n1-和 - (CH2)n2-连接,以及作为肾外膜(ROMK)通道(Kir1.1)的抑制剂的药学上可接受的盐。 这些化合物可用作利尿剂和利尿钠,因此可用于治疗和预防由过度的盐和水分滞留引起的疾病,包括心血管疾病如高血压和慢性和急性心力衰竭。
-
公开(公告)号:US20220259188A1
公开(公告)日:2022-08-18
申请号:US17614732
申请日:2020-06-01
Applicant: Hua ZHOU , John J. ACTON, III , Michael J. ARDOLINO , Yi-Heng CHEN , Peter H. FULLER , Anmol GULATI , Rebecca Elizabeth JOHNSON , William P. KAPLAN , Solomon D. KATTAR , Mitchell H. KEYLOR , Derun LI , Kaitlyn Marie LOGAN , Min LU , Gregori J. MORRIELLO , Santhosh F. NEELAMKAVIL , Barbara PIO , Nunzio SCIAMMETTA , Vladimir SIMOV , Jing SU , Luis TORRES , Xin YAN , Merck Sharp & Dohme Corp.
Inventor: Hua Zhou , John J. Acton, III , Michael J. Ardolino , Yi-Heng Chen , Peter H. Fuller , Anmol Gulati , Rebecca Elizabeth Johnson , William P. Kaplan , Solomon D. Kattar , Mitchell H. Keylor , Derun Li , Kaitlyn Marie Logan , Min Lu , Gregori J. Morriello , Santhosh F. Neelamkavil , Barbara Pio , Nunzio Sciammetta , Vladimir Simov , Jing Su , Luis Torres , Xin Yan
IPC: C07D405/14 , C07D487/08 , C07D409/14 , C07D403/04 , C07D403/14 , C07D498/04 , C07D498/08 , C07D487/10 , C07D401/14 , C07D471/10 , C07D491/107 , C07D471/04 , C07D487/04 , A61P25/16
Abstract: The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.
-
公开(公告)号:US10662171B2
公开(公告)日:2020-05-26
申请号:US15328908
申请日:2015-08-03
Applicant: Merck Sharp & Dohme Corp.
Inventor: Harry Chobanian , Duane DeMong , Yan Guo , Barbara Pio , Christopher W. Plummer
IPC: C07D335/06 , C07D213/64 , C07D311/04 , A61K45/06 , A61K31/453 , A61K31/44 , A61K31/353 , A61K31/192 , A61K31/352 , C07D311/20 , A61K31/366 , A61K31/382 , C07D405/04 , A61K31/444 , C07D405/10
Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
公开(公告)号:US10000484B2
公开(公告)日:2018-06-19
申请号:US15101467
申请日:2014-12-16
Applicant: MERCK SHARP & DOHME CORP. , Harry Chobanian , Barbara Pio , Yan Guo , Fa-Xiang Ding , Shuzhi Dong , Shawn P. Walsh , Jinlong Jiang , Dooseop Kim
Inventor: Harry Chobanian , Barbara Pio , Yan Guo , Fa-Xiang Ding , Shuzhi Dong , Shawn P. Walsh , Jinlong Jiang , Dooseop Kim
IPC: A61K31/4355 , A61K31/437 , A61K31/4985 , A61K31/519 , A61K31/55 , C07D471/04 , C07D487/04 , C07D498/04 , A61K31/401 , A61K31/4178 , A61K31/424 , A61K31/4422 , A61K31/496 , A61K31/4965 , A61K31/585 , A61K45/06
CPC classification number: C07D471/04 , A61K31/401 , A61K31/4178 , A61K31/424 , A61K31/437 , A61K31/4422 , A61K31/496 , A61K31/4965 , A61K31/4985 , A61K31/519 , A61K31/55 , A61K31/585 , A61K45/06 , C07D487/04 , C07D498/04 , A61K2300/00
Abstract: The present invention provides compounds of Formula (I) (Formula (I)) including pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.
-
公开(公告)号:US09957219B2
公开(公告)日:2018-05-01
申请号:US15034189
申请日:2014-12-01
Applicant: Merck Sharp & Dohme Corp.
Inventor: Thomas Bara , Harry R. Chobanian , Yan Guo , Hubert Josien , Michael Miller , Barbara Pio , Christopher W. Plummer , Cangming Yang , Dong Xiao
IPC: C07C59/72 , A61K45/06 , A61K31/192 , A61K31/404 , A61K31/435 , C07D221/04 , C07D231/12 , C07D207/333 , C07D277/42 , C07D209/12 , A61K31/277 , A61K31/381 , A61K31/415 , A61K31/4192 , A61K31/427 , A61K31/437 , A61K31/44 , C07C255/59 , C07D209/08 , C07D213/64 , C07D249/04 , C07D333/24 , C07D417/04 , C07D471/04
CPC classification number: C07C59/72 , A61K31/192 , A61K31/277 , A61K31/381 , A61K31/404 , A61K31/415 , A61K31/4192 , A61K31/427 , A61K31/435 , A61K31/437 , A61K31/44 , A61K45/06 , C07C255/59 , C07C2601/02 , C07C2601/14 , C07C2602/06 , C07C2602/08 , C07D207/333 , C07D209/08 , C07D209/12 , C07D213/64 , C07D221/04 , C07D231/12 , C07D249/04 , C07D277/42 , C07D333/24 , C07D417/04 , C07D471/04 , A61K2300/00
Abstract: Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment, prevention and suppression of diseases mediated by the G-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of Type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia.
-
-
-
-
-
-
-
-
-